Photo: Interventional team at work. Ritu Chauhan / Unsplash
1. Sirtex acquires FDA-cleared Hourglass vascular plug for peripheral embolization
The plug joins the company's LAVA liquid embolic in its embolization portfolio.
Sirtex Medical said Nov. 16 it has acquired the Hourglass Vascular Plug, an embolization device with FDA 510(k) clearance first granted in 2017 and previously sold in the U.S. through a limited market release [1]. The plug is indicated to slow or block blood flow in peripheral vessels 6 to 8 mm in diameter, and Sirtex says it complements its LAVA Liquid Embolic System [1]. Deal terms were not disclosed; the company said it is completing the work needed to make the device available to physicians and will share availability details later [1].
2. FDA approves Genentech's Wilserdly plus everolimus for ESR1-mutated advanced breast cancer
The oral estrogen receptor antagonist cut the risk of progression by more than half.
The FDA on Nov. 16 approved Wilserdly (giredestrant) with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer that recurred or progressed after endocrine therapy, four weeks ahead of its goal date [2]. In the randomized, open-label evERA trial, the 207 patients with ESR1 mutations had a median progression-free survival of 10 months on giredestrant plus everolimus versus 5.5 months on physician's-choice endocrine therapy plus everolimus, a hazard ratio of 0.38 [2]. FoundationOne Liquid CDx was authorized as the companion diagnostic, and warnings include bradycardia and embryo-fetal toxicity [2].
3. CMS proposes CRUSH anti-fraud rule with nearly $90 billion in projected savings
Medicare Advantage RADV audits would be extrapolated starting with payment year 2018.
CMS on Nov. 16 issued the Comprehensive Regulations to Uncover Suspicious Healthcare, or CRUSH, proposed rule (CMS-6098-P), which spans Medicare, Medicaid, CHIP and the Marketplace and which the agency says it intends to issue annually [3]. The rule would codify that CMS will not apply a fee-for-service adjuster to risk adjustment data validation audits and would extrapolate audit findings beginning with payment year 2018, recovering an estimated $9 billion per payment year in Medicare Advantage overpayments [3]. CMS projects nearly $90 billion in federal savings against about $378.5 million in costs from 2027 through 2036; comments are due 60 days after Federal Register publication [3].
4. FDA proposes first-of-its-kind rule allowing NAC to be sold as a dietary supplement
The agency says it found no safety concerns with N-acetyl-L-cysteine as a supplement.
The FDA on Nov. 16 issued a proposed rule that would reverse the exclusion of N-acetyl-L-cysteine from the definition of a dietary supplement, four years after the agency concluded in March 2022 that NAC products could not be marketed that way [4]. It is the FDA's first use of the rulemaking authority in the exclusion provision and would create a new regulation listing ingredients not excluded from the supplement definition, with NAC as the first entry [4]. The agency will continue its 2022 enforcement discretion for NAC supplements while the rule, open for comment for 60 days, moves forward [4].
Digest references
Sirtex Medical, "Sirtex Medical Acquires Hourglass Vascular Plug," Nov. 16, 2026. sirtex.com
U.S. Food and Drug Administration, "FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer," Nov. 16, 2026. fda.gov
Centers for Medicare & Medicaid Services, "Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) Proposed Rule (CMS-6098-P)," Nov. 16, 2026. cms.gov
U.S. Food and Drug Administration, "FDA Issues Proposed Rule on NAC Products as Dietary Supplements," Nov. 16, 2026. fda.gov